Effect of theophylline on stent-related symptoms in patients undergoing Double-J ureteral stent insertion: a randomized controlled trial.

Autor: Pakdel A; Urology Research Center, Tehran University of Medical Sciences, Tehran, Iran., Mohammadi A; Urology Research Center, Tehran University of Medical Sciences, Tehran, Iran., Chivaee H; Urology Research Center, Tehran University of Medical Sciences, Tehran, Iran., Shamshirgaran A; Urology Research Center, Tehran University of Medical Sciences, Tehran, Iran., Amirzargar H; Section of Tissue Engineering and Stem Cells Therapy, Pediatric Urology and Regenerative Medicine Research Center, Children's Hospital Medical Center, Tehran University of Medical Sciences, Tehran, Iran., Farsani RM; Urology Research Center, Tehran University of Medical Sciences, Tehran, Iran., Asgari F; Urology Research Center, Tehran University of Medical Sciences, Tehran, Iran., Khajavi A; Urology Research Center, Tehran University of Medical Sciences, Tehran, Iran.; Student Research Committee, School of Allied Medical Sciences, Shahid Beheshti University of Medical Sciences, Tehran, Iran., Aghamir SMK; Urology Research Center, Tehran University of Medical Sciences, Tehran, Iran. mkaghamir@tums.ac.ir.
Jazyk: angličtina
Zdroj: International urology and nephrology [Int Urol Nephrol] 2024 Sep; Vol. 56 (9), pp. 2897-2903. Date of Electronic Publication: 2024 Apr 17.
DOI: 10.1007/s11255-024-04049-x
Abstrakt: Purpose: To investigate the effect of oral theophylline on stent-related syndrome (SRS) after Double-J insertion.
Background: Double-J stent is widely using in many urological procedures. Infection, hematuria, and discomfort are some of common complication after stenting. Theophylline is a dimethylated xanthine that inhibits phosphodiesterase and blocks adenosine receptors. To relaxing effect of theophylline on smooth muscles and its effects on the urinary system, it seems it could reduce complications after inserting Double-J stent especially ureteral stent syndrome.
Method: In this double-blind placebo-controlled randomized clinical trial, 67 patients were enrolled. Mean (SD) age of control and theophylline group was 51.8 (12.5) and 43.9 (10.4) years old, respectively. Patients were randomized into two groups of control and theophylline. All patients were stenting with silicon Double J. Theophylline group received 100 mg of theophylline, twice daily for 30 days, while control group received placebo. Stent symptoms were assessed by questionnaire and urine culture was performed before stent removal at removal day. Statistical analysis was performed using Chi-squared test and t test with P < 0.05 considered significant. Logistic regression models were fitted, crudely and adjusted for age and sex.
Result: Of 67 eligible patients, 60 completed the study. Theophylline significantly decreased percentages of gross hematuria (P < 0.001), dysuria (P < 0.001), and urinary frequency (P < 0.001). Microscopic hematuria (P = 0.042) and chills (P = 0.042) also decreased after theophylline.
Conclusion: Theophylline could be an effective and safe choice for reducing SRS among patients undergoing Double-J stent insertion.
(© 2024. The Author(s), under exclusive licence to Springer Nature B.V.)
Databáze: MEDLINE
Externí odkaz: